BTAX: AI 评分 47/100 — AI 分析 (4月 2026)

Biostax Corp. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products, including its lead drug candidate Lodonal for HIV/AIDS. The company also explores telehealth platforms and blockchain solutions for healthcare, operating in the competitive biotechnology sector.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Biostax Corp., formerly Immune Therapeutics, is a biopharmaceutical company developing Lodonal for HIV/AIDS and exploring telehealth and blockchain applications in healthcare. Operating in the biotechnology sector, the company focuses on acquiring and commercializing pharmaceutical products, facing competition from established and emerging players while navigating regulatory and funding challenges.

BTAX是做什么的？

Biostax Corp., formerly known as Immune Therapeutics, Inc., was rebranded in October 2023 and operates as a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products. The company's lead investigational drug candidate is Lodonal, an oral, once-a-day immune system regulator being developed for the management of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). Beyond Lodonal, Biostax is also pursuing a Global Telehealth platform, aiming to provide remote healthcare solutions. The company is also developing a Medtech asset, an early-stage program leveraging blockchain and smart contracts to manage and secure prescriptions and electronic health records. Another key asset is JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist being developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Additionally, Biostax is exploring Low Dose Naltrexone, a compound formula purported to provide immune-modulating benefits for conditions including cancer, pain, autoimmune disorders, and anti-aging. The company also has programs for the treatment of hyperphosphatemia. Biostax has a licensing agreement with Cytocom Inc. and is headquartered in Winter Park, Florida.

BTAX的投资论点是什么？

Biostax Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful development and commercialization of Lodonal for HIV/AIDS, a market with ongoing medical needs. Further potential lies in the development of JKB-122 for liver diseases like NAFLD and NASH. Growth catalysts include positive clinical trial results for Lodonal and JKB-122, strategic partnerships, and successful navigation of regulatory hurdles. However, the company faces significant risks, including the need for additional funding, potential clinical trial failures, and competition from established pharmaceutical companies. The company's market capitalization is $0.00B, reflecting the speculative nature of its pipeline and early-stage development programs.

BTAX在哪个行业运营？

Biostax Corp. operates in the highly competitive biotechnology industry, characterized by intense research and development, lengthy regulatory approval processes, and significant capital requirements. The industry is driven by innovation and the development of new therapies for unmet medical needs. Key trends include the rise of personalized medicine, the increasing use of data analytics and artificial intelligence, and the growing importance of strategic partnerships. Biostax competes with both large pharmaceutical companies and smaller biotech firms, including companies developing therapies for HIV/AIDS, liver diseases, and other conditions. The company's success depends on its ability to develop and commercialize innovative products, secure funding, and navigate the complex regulatory landscape.

Biotechnology

Healthcare

BTAX有哪些增长机遇？

Lodonal Development and Commercialization: The successful development and commercialization of Lodonal for HIV/AIDS represents a significant growth opportunity for Biostax. The global HIV/AIDS market is expected to continue to grow, driven by increasing prevalence and the need for improved therapies. If Lodonal demonstrates superior efficacy and safety compared to existing treatments, it could capture a significant share of the market. The timeline for this growth opportunity depends on the successful completion of clinical trials and regulatory approval, potentially within the next 3-5 years.
JKB-122 for Liver Diseases: The development of JKB-122 for autoimmune hepatitis, NAFLD, and NASH represents another significant growth opportunity. These liver diseases are becoming increasingly prevalent, driven by factors such as obesity and diabetes. There is a significant unmet need for effective therapies, and JKB-122, as a TLR4 antagonist, has the potential to address this need. The timeline for this growth opportunity depends on the successful completion of clinical trials and regulatory approval, potentially within the next 4-6 years.
Global Telehealth Platform: Biostax's development of a Global Telehealth platform offers a growth opportunity in the expanding telehealth market. The telehealth market is experiencing rapid growth, driven by increasing demand for remote healthcare services and technological advancements. By providing a comprehensive telehealth platform, Biostax can potentially capture a share of this growing market. The timeline for this growth opportunity depends on the successful development and launch of the platform, potentially within the next 2-3 years.
Medtech Asset with Blockchain Technology: The development of a Medtech asset using blockchain and smart contracts for managing prescriptions and electronic health records presents a novel growth opportunity. Blockchain technology offers the potential to improve the security and efficiency of healthcare data management. By leveraging blockchain, Biostax can potentially create a competitive advantage in the Medtech market. The timeline for this growth opportunity depends on the successful development and implementation of the blockchain-based system, potentially within the next 3-4 years.
Low Dose Naltrexone (LDN) Applications: Exploring the potential of Low Dose Naltrexone (LDN) for immune-modulating benefits in areas like cancer, pain, autoimmune disorders, and anti-aging opens up diverse growth avenues. While the scientific evidence for LDN's efficacy in these areas is still evolving, positive clinical data could lead to significant market opportunities. The timeline for this growth opportunity is dependent on further research and clinical trials, potentially yielding results within the next 3-5 years.

Biostax Corp.'s lead drug candidate, Lodonal, targets the HIV/AIDS market, representing a significant unmet medical need.
The company is exploring blockchain technology for healthcare applications, potentially creating new revenue streams and competitive advantages.
Biostax Corp. has a licensing agreement with Cytocom Inc., potentially providing access to additional technologies and expertise.
The company's pipeline includes JKB-122, targeting autoimmune hepatitis, NAFLD, and NASH, addressing a growing market with limited treatment options.
Biostax Corp. changed its name from Immune Therapeutics, Inc. in October 2023, signaling a potential shift in strategy or focus.

BTAX提供哪些产品和服务？

Acquires pharmaceutical and biotechnology products.
Develops pharmaceutical products, including Lodonal for HIV/AIDS.
Commercializes pharmaceutical products.
Develops a Global Telehealth platform for remote healthcare.
Develops a Medtech asset using blockchain for secure prescription management.
Develops JKB-122 for autoimmune hepatitis, NAFLD, and NASH.
Explores Low Dose Naltrexone for immune-modulating benefits.
Develops programs for the treatment of hyperphosphatemia.

BTAX如何赚钱？

Develops and patents pharmaceutical products.
Out-licenses or partners for commercialization of developed products.
Acquires rights to existing pharmaceutical products.
Generates revenue through product sales, licensing fees, and milestone payments.

Patients with HIV/AIDS (Lodonal).
Patients with autoimmune hepatitis, NAFLD, and NASH (JKB-122).
Healthcare providers using the Global Telehealth platform.
Pharmacies and healthcare organizations using the Medtech asset.
Patients seeking immune-modulating benefits (Low Dose Naltrexone).

Patent protection for developed pharmaceutical products.
Proprietary formulations and drug delivery systems.
Strategic partnerships and licensing agreements.
First-mover advantage in specific therapeutic areas or technologies.

什么因素可能推动BTAX股价上涨？

Upcoming: Clinical trial results for Lodonal in HIV/AIDS patients.
Upcoming: Regulatory submissions for JKB-122 for autoimmune hepatitis, NAFLD, and NASH.
Ongoing: Development and launch of the Global Telehealth platform.
Ongoing: Progress in the Medtech asset development using blockchain technology.
Ongoing: Exploration of Low Dose Naltrexone applications and clinical trials.

BTAX的主要风险是什么？

Potential: Clinical trial failures for Lodonal or JKB-122.
Potential: Regulatory delays or rejections.
Potential: Competition from established pharmaceutical companies.
Ongoing: Need for additional funding to support operations and development.
Ongoing: Dependence on key personnel and strategic partnerships.

BTAX的核心优势是什么？

Diverse pipeline of pharmaceutical and biotechnology products.
Focus on unmet medical needs.
Potential for breakthrough therapies.
Exploration of innovative technologies like blockchain and telehealth.

BTAX的劣势是什么？

Limited financial resources.
Early-stage development programs.
Dependence on successful clinical trials.
Lack of established commercial infrastructure.

BTAX有哪些机遇？

Strategic partnerships with larger pharmaceutical companies.
Out-licensing of developed products.
Expansion into new therapeutic areas.
Acquisition of complementary technologies or assets.

BTAX面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established pharmaceutical companies.
Patent expirations.
Need for additional funding.

BTAX的竞争对手是谁？

Aridis Pharmaceuticals Inc — Focuses on novel anti-infective therapies. — (ARDS)
Evelo Biosciences Inc — Develops orally delivered biologicals. — (EVLO)
GS Healthcare Acquisition Corp — Specializes in healthcare acquisitions. — (GSRX)
Health Sciences Technologies Corp — Focuses on medical device technologies. — (HSTC)
Infinity Q Volatility Alpha Fund — Investment fund with healthcare holdings. — (INFIQ)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Noreen Griffin
Headquarters: Winter Park, US
Founded: 2010

AI Insight

AI analysis pending for BTAX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Biostax Corp. do?

Biostax Corp. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its primary focus is on developing Lodonal, an investigational drug candidate for the management of HIV/AIDS. Additionally, the company is exploring opportunities in telehealth, blockchain technology for healthcare data management, and treatments for liver diseases like autoimmune hepatitis, NAFLD, and NASH. Biostax aims to address unmet medical needs through innovative therapies and technologies.

What do analysts say about BTAX stock?

AI analysis is pending for BTAX stock. Generally, micro-cap biotechnology companies like Biostax are viewed as high-risk, high-reward investments due to the uncertainty of drug development and regulatory approval processes. Key valuation metrics to consider include the potential market size for Lodonal and JKB-122, the probability of successful clinical trials, and the company's cash runway. Investors should conduct thorough due diligence and consider their risk tolerance before investing.

What are the main risks for BTAX?

The main risks for Biostax Corp. include the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company also faces financial risks, including the need for additional funding to support operations and development. As an OTC-listed company, BTAX is subject to lower liquidity and disclosure requirements, increasing the risk of volatility and potential manipulation. Investors should carefully consider these risks before investing.